Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government
Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5
receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells
that fight infection). Previous studies in HIV treatment-experienced patients have shown that
vicriviroc is safe and effective. The purpose of this study is to determine the effect of
vicriviroc on HIV RNA levels in cerebrospinal fluid (CSF).